Elevated serum miR-133a predicts patients at risk of periprocedural myocardial injury after elective percutaneous coronary intervention.

CONCLUSIONS: This study demonstrates for the first time that serum miR-133a can be used as a novel biomarker for early identification of stable CAD patients at risk of PMI undergoing elective PCI. The miR-133a-FGFR1 axis may be involved in the pathogenesis of PMI. PMID: 32207842 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32207842?dopt=Abstract

Source: Cardiology Journal - March 23, 2020 Category: Cardiology Authors: Zhou Y, Chen Z, Chen A, Ma J, Qian J, Ge J Tags: Cardiol J Source Type: research